-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

612.O1.6 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Management of Novel ALL Subsets in Different Age Groups

Symposia: Acute Lymphoblastic Leukemias: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Biological therapies, clinical trials, adult, Translational Research, Combination therapy, Clinical Research, drug development, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Adverse Events, Study Population, Human, Transplantation, Minimal Residual Disease
Saturday, December 10, 2022: 9:30 AM-11:00 AM
243-245 (Ernest N. Morial Convention Center)
Moderators:
Hiroto Inaba, MD, PhD, St. Jude Children's Research Hospital and Deborah Yallop, MBBS, FRCP, FRCPATH, PHD, King's College Hospital NHS Trust
Disclosures:
Yallop: Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Other: Meeting support, Research Funding; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Meeting Support.
This acute lymphoblastic leukemia (ALL)-focused session includes globally represented abstracts encompassing children, adolescents, young adults and the elderly.  Abstracts in this session report the results of important clinical studies aimed at improving outcomes among particularly difficult to treat subsets of both B- and T-cell ALL.  The findings highlight important approaches to improved risk stratification leveraging clinical factors, genomics and minimal residual disease.  Novel approaches to therapy are explored including intensification of standard chemotherapy, pediatric inspired chemotherapy regimens for elderly adults and the addition of nelarabine plus intensification of asparaginase for adults with T-ALL. The results presented in this session lend support to the idea that for pediatric ALL, we have likely hit the ceiling of therapy intensification as a means to further improve outcomes.  Data presented in this session also reveal that among adults with ALL, through refined age- and risk-adapted therapy, further improvements in outcome may be attainable.
9:30 AM

Valentino Conter, MD1*, Maria Grazia Valsecchi, PhD2*, Gunnar Cario, MD, PhD3*, Martin Zimmermann, PhD4*, Andishe Attarbaschi, MD5*, Jan Stary, MD6,7*, Felix Niggli, MD8*, Luciano Dalla Pozza, MD9*, Sarah Elitzur, MD10*, Daniela Silvestri, Dr11*, Franco Locatelli, Prof., MD, PhD12, Anja Moericke, MD13*, Gernot Engstler, MD14*, Petr Smisek, MD6*, Nicole Bodmer, MD15*, Draga Barbaric, MBBS FRACP16*, Shai Izraeli, MD17, Carmelo Rizzari18*, Joachim Boos, MD19*, Barbara Buldini20*, Claudia Lanvers-Kaminsky, PhD21*, Giovanni Cazzaniga, PhD22, Bernd Gruhn23*, Andrea Biondi, MD, PhD24 and Martin Schrappe, MD13

1Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
2Bicocca Bioinformatics, Biostatistics and Bioimaging Centre, Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy
3Universitätsklinikum Schleswig-Holstein, Kiel, Germany
4Department of Pediatric Hematology and Oncology, Hannover Medical School (MHH), Hannover, Germany
5St. Anna Children's Hospital, Vienna, Austria
6Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
7Dept. of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
8University Children's Hospital, Zurich, Switzerland, CHE
9Cancer Centre for Children, Children’s Medical Research Institute (CMRI), Westmead, NSW, Australia
10Pediatric Hematology and Oncology, Schneider Children's Medical Center and Tel Aviv University, Tel Aviv, Israel
11Bicocca Center of Bioinformatics, Biostatstics and Bioimaging, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy
12Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù Rome, Catholic University of the Sacred Heart, Rome, Italy
13Department of Pediatrics I, Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
14St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
15University Children's Hospital Zürich, Zürich, Switzerland
16Kids Cancer Centre, Sydney Children’s Hospital Randwick, Randwick, Australia
17Department of Pediatric Hematology Oncology, Schneider Children Medical Center of Israel, Petach Tikva, Israel
18Pediatric Hematology-Oncology Unit, University of Milano-Bicocca, MBBM Foundation, San Gerardo Hospital, Monza, Italy
19Department of Pediatric Hematology and Oncology, University Childrens’ Hospital of Münster, Münster, Germany
20University of Padua, Padua, It, Italy
21Paediatric Haematology and Oncology, University Hospital of Muenster, Muenster, NRW, DEU
22Dept. of Pediatrics / Medical Genetics and Tettamanti Research Center, University of Milano-Bicocca, Fondazione MBBM / San Gerardo Hospital, Monza, Italy
23Department of Pediatrics, Jena University Hospital, Jena, Germany
24Department of Medicine, University of Milano-Bicocca, Monza, Italy

9:45 AM

Nicolas Boissel, MD, PhD1,2, Francoise Huguet, MD3*, Thibaut Leguay, MD4*, Hunault-Berger Mathilde, MD, PhD5*, Carlos Graux6*, Yves Chalandon, MD7, Eric Delabesse, MD, PhD8*, Yosr Hicheri, MD9*, Patrice Chevallier, MD10, Marie Balsat11*, Cedric Pastoret, MD, PhD12*, Martine Escoffre-Barbe, MD13*, Florence Pasquier, MD, PhD14*, Jean-Pierre Marolleau, MD, PhD15, Anne Thiebaut-Bertrand16*, Anne Huynh17*, Nathalie Dhedin, MD18*, Emilie Lemasle, MD19*, Caroline Bonmati, MD20*, Sébastien Maury21*, Gaëlle Guillerm, MD22*, Anna Berceanu, MD23*, Urs Schanz, MD24, Thomas Cluzeau, MD, PhD25, Pascal Turlure, MD26*, Philippe Rousselot, MD, PhD27*, Bernard J. M. De Prijck, MD28*, Nathalie Grardel, MD29*, Marie C Bene, PharmD, DPhil30*, Marine Lafage, MD31*, Norbert Ifrah, MD PhD32, Veronique Lheritier33*, Vahid Asnafi, MD, PhD34,35*, Emmanuelle Clappier, PharmD, PhD36* and Herve Dombret, MD PhD37,38

1St-Louis Hospital, APHP, Adolescent and Young Adult Hematology Department, Paris, France
2URP-3518, Saint-Louis Research Insitute, Université Paris Cité, Paris, France
3Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France
4Hematology Clinic, Bordeaux University Hospital, Pessac, France
5department of hematology, CHU Angers, Angers, ML, France
6Université Catholique de Louvain, CHU UCL Namur (Godinne), Yvoir, Belgium
7Geneva University Hospitals, Geneva, Switzerland
8FRA
9Departement d'Hematologie, Institut Paoli-Calmettes, MARSEILLE, France
10Hematology Department, Nantes University Hospital, Nantes, France
11Service Hematologie, Centre Hospitalier Lyon Sud, Lyon, France
12INSERM U1236 /Hematology Laboratory, University Hospital of Rennes, RENNES, FRA
13Hôpital de Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
14Gustave Roussy, Département clinique d'hématologie, INSERM UMR1170, Villejuif, FRA
15Hematology Department, Amiens University Hospital, Amiens, France
16Department of Hematology, CHU-Grenoble Onco-Hematologie, Grenoble, France
17Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
18St-Louis Hospital, APHP, Adolescents and Young Adults Hematology Department, Paris, France
19Hematology Department, Henri-Becquerel Cancer Center, Rouen, France
20Service D'Hématologie, Centre Hospitalier Universitaire De Nancy, Nancy, FRA
21Service d’Hématologie clinique, Hôpitaux universitaires Henri-Mondor (AP-HP), Créteil, FRA
22Department of Hematology, Brest University Hospital, Brest, France
23Clinical Hematology, Besançon University Hospital, Besançon, France
24Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
25Département d'Hématologie Clinique, Université Côte d'Azur, CHU Nice, Nice, Provence Alpes Cote d'Azur, France
26Department of Clinical Hematology, Limoges University Hospital, Limoges, France
27Hematology Department, Centre Hospitalier de Versailles, LE CHESNAY CEDEX, France
28CHU Sart Tilman, Liege, BEL
29Laboratory of Hematology, Centre Hospitalier Universitaire Lille, Lille, France
30Hematology Biology, Nantes University Hospital, Nantes, France
31Department of Genetics, La Timone Hospital, Aix Marseille University, MARSEILLE, France
32Clinical Hematology, Angers University Hospital, Angers, France
33Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), Centre Hospitalier Lyon Sud, Lyon, France
34INSERM U1151, Université Paris Descartes Sorbonne Cité, Paris, France
35Laboratory of Onco-Hematology, Necker University Hospital, Paris, France
36Hematology Laboratory, AP-HP, Hôpital Saint-Louis, Paris, France
37URP-3518, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France
38Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA

10:00 AM

Nicola Goekbuget, MD1, Walter Fiedler, MD2, Nael Alakel, MD3*, Max S. Topp, MD4*, Maher Hanoun, MD5*, Björn Steffen, MD1*, Ralph Wäsch6, Andreas Viardot, MD7, Kathrin Nachtkamp, MD8*, Matthias Stelljes, MD9*, Hendrik Poeck, MD10, Vladan Vucinic, MD11*, Boris Böll, MD12*, Joachim Beck, MD13*, Lars Fransecky, MD14*, Knut Wendelin, MD15*, Folker Schneller, MD16*, Christoph Faul, MD17, Veit L Buecklein, MD18*, Lena Reiser1*, Monika Brüggemann, MD19*, Hubert Serve, MD1 and Stefan Schwartz, M.D.20*

1Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany
2Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Hospital Eppendorf, Hamburg, Germany
3University Hospital TU Dresden, Germany, Dresden, Germany
4UniversitäTsklinikum WüRzburg, Würzburg, Germany
5Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
6Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
7Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
8Department of Hematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany
9University Hospital of Muenster, Muenster, Germany
10Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Bavaria, Germany
11Department for Hematology, Cell Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany
12Hematology/Oncology, University Hospital Cologne, Cologne, NRW, Germany
13Universitatsmedizin Mainz, Mainz, Schkeuditz, Germany
14Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany
15Paracelsus Medizinische Privatuniversität Nürnberg, Klinik f. Innere Medizin 5, Nuernberg, Germany
16Medical Department III, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
17University Hospital Tübingen, Department of Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, Tübingen, Germany
18Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
19Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Kiel, Germany
20Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

10:15 AM

Ruth Wangondu, MD, PhD1, Emily Ashcraft, MPH2*, Kathryn G Roberts, PhD3, Cheng Cheng, PhD2*, Hiroto Inaba, MD, PhD1 and Charles G. Mullighan, MBBS, MD3

1Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
2Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
3Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN

10:30 AM

Nicola Goekbuget, MD1, Andreas Viardot, MD2, Björn Steffen, MD1*, Joachim Hahn, MD3*, Bernd Spriewald, MD4*, Sonja Martin, MD5*, Simon Raffel, MD6, Lino L. Teichmann, MD7*, Arne Trummer, MD8*, Winfried Alsdorf, MD9*, Anke Morgner, MD10*, Stefan Schwartz, M.D.11*, Matthias Stelljes, Prof. Dr. med.12, Vladan Vucinic, MD13*, Nael Alakel, MD14*, Andrea Stoltefuß, MD15*, Claudia D. Baldus, MD16*, Monika Brüggemann, MD16*, Hubert Serve, MD1 and Dieter Hoelzer, MD, PhD17

1Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany
2Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
3Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany
4Med. Klinik 5 / Hämatologie u. Internist. Onkologie, Universität Erlangen-Nürnberg, Erlangen, Germany
5Department of Hematology and Oncology, Robert-Bosch-Hospital, Stuttgart, Germany
6Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
7Department of Medicine III, University Hospital Bonn, Bonn, Germany
8Department of Internal Medicine III, Braunschweig Municipial Hospital, Braunschweig, Germany
9Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
10Klinikum Chemnitz, Chemnitz, Germany
11Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
12Department of Medicine / Hematology and Oncology, University of Muenster, Muenster, Germany
13Department for Hematology, Cell Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany
14University Hospital TU Dresden, Germany, Dresden, Germany
15Evangelisches Krankenhaus Hamm, Hamm, Germany
16Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Kiel, Germany
17Onkologikum Frankfurt, Frankfurt, Germany

10:45 AM

Yoshihiro Hatta1, Atsushi Sato, MD, PhD2*, Akiko Kada, MPH3*, Akiko Moriya Saito, MD, PhD3*, Fumihiko Hayakawa, MD, PhD4, Arata Watanabe, MD5*, Tatsuhiro Sakamoto, MD, PhD6*, Katsuhiro Miura, MD7*, Yoshifumi Shimizu, MD8*, Junya Kanda, MD, PhD9, Yasushi Onishi, MD, PhD10*, Noboru Asada, MD, PhD11, Yasuhiro Okamoto, MD, PhD12, Chihaya Imai, MD, PhD13, Koichi Oshima, MD, PhD14*, Katsuyoshi Koh, MD14*, Atsushi Manabe, MD, PhD15, Keizo Horibe, MD, PhD3,16*, Hitoshi Kiyoi17, Itaru Matsumura18 and Yasushi Miyazaki, MD19

1Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
2Department of Hematology and Oncology, Miyagi Children’s Hospital, Sendai, Japan
3Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
4Department of Integrated Health Sciences, Division of Cellular and Genetic Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
5Department of Pediatrics, Nakadori General Hospital, Akita, JPN
6Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
7Division of Hematology and Rheumatology, Department of Medicine, Nihon University, Tokyo, Japan
8Department of Hematology, Takarazuka City Hospital, Takarazuka, Japan
9Department of Hematology and Oncology, Kyoto University, Kyoto, Japan
10Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan
11Department of Hematology and Oncology, Okayama University Hospital, Okayama, OKA, Japan
12Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
13Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
14Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
15Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
16Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
17Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya-shi, Japan
18Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osakasayama, Japan
19Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

*signifies non-member of ASH